Xenetic Biosciences Inc
xeneticbio.comXenetic Biosciences (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company focused on researching and developing oncology drug candidates built on its proprietary platform technologies. Revenue comes from royalties on licensed technologies, which totaled $2,976,411 in FY2025, up 19.0% from $2,500,284 in FY2024. The company does not generate product sales and operates at a loss, with a net loss of $2,680,860 in FY2025 versus $3,960,275 in FY2024. Internal development efforts in FY2025 centered on the DNase technology, which targets neutrophil extracellular traps (NETs) implicated in cancer pathogenesis and resistance to existing therapies including immune checkpoint inhibitors. XCART and PolyXen, two other platform technologies, were not actively pursued during FY2025. Xenetic has no manufacturing, sales, marketing, or distribution capabilities and relies on contract research organizations (CROs) and contract manufacturing organizations (CMOs) to conduct pre-clinical and clinical work.
Products & Services
DNase technology (primary internal development focus in FY2025) targeting NETs in oncology, including metastatic colorectal cancer (mCRC). XCART and PolyXen platform technologies held but not actively developed in FY2025.
Revenue Model
Royalty revenue from licensed technologies is the sole revenue stream, totaling $2,976,411 in FY2025. The company expenses all research and development costs as incurred and does not generate product revenue.
Customers & Markets
End markets are oncology patients, with a focus on metastatic colorectal cancer, including the MSS/MMRp subset (greater than 90% of mCRC patients) where immune checkpoint inhibitors have shown no benefit. Royalty revenue derives from biotechnology and pharmaceutical collaborators licensing Xenetic's platform technologies.
Geographic Exposure
The filing does not specify geographic revenue breakdown.
Financial Snapshot
Loading...
